FEED

ENvue Medical, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.45
52-Week Range: $0.23 – $89.40
Market Cap: $406.44K
P/E (TTM): —
EPS (TTM): -339.36
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.01
PEG Ratio: —
Return on Equity: -59.14%
Return on Assets: -20.99%
Gross Margin: -26.06%
Operating Margin: -2290.38%
Profit Margin: 0.00%
Current Ratio: 0.66
Debt/Equity: 0.04
Total Debt: $1.31M
Free Cash Flow: $-5.82M
Revenue Growth: -51.60%
Earnings Growth: —
Enterprise Value: $632.34K

FEED Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$752.00K	$2.28M	$2.56M	$2.55M
Cost of Revenue	$585.00K	$746.00K	$1.05M	$2.40M
Gross Profit	$167.00K	$1.54M	$1.51M	$153.00K
Research & Development	$283.00K	$185.00K	$909.00K	$1.76M
Selling, General & Admin	$4.90M	$4.79M	$4.18M	$10.13M
Operating Expenses	$5.18M	$4.97M	$5.09M	$11.89M
Operating Income	-$5.01M	-$3.44M	-$3.58M	-$11.73M
EBITDA	-$5.07M	-$3.55M	-$3.58M	-$10.84M
Pretax Income	-$5.41M	-$3.68M	-$3.69M	-$18.49M
Income Tax	$35.00K	$29.00K	$19.00K	-$307.00K
Net Income	-$5.45M	-$3.71M	-$3.71M	-$18.18M
Diluted EPS	-422.40	-233.20	-137.30	-26.69
Diluted Shares	12906	15910	26985	628534

FEED Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.71M	$3.28M	$752.00K	$4.22M
Receivables	$109.00K	$425.00K	$268.00K	$543.00K
Inventory	$2.17M	$2.73M	$2.19M	$2.34M
Current Assets	$5.61M	$6.49M	$3.33M	$7.27M
Total Assets	$5.88M	$6.67M	$3.63M	$41.12M
Current Liabilities	$2.32M	$2.45M	$2.72M	$6.66M
Total Debt	$81.00K	$5.00K	$116.00K	$1.20M
Total Liabilities	$2.65M	$2.69M	$3.00M	$7.63M
Retained Earnings	-$62.38M	-$66.10M	-$69.80M	-$90.48M
Shareholders' Equity	$3.23M	$3.99M	$627.00K	$33.50M
Working Capital	$3.29M	$4.03M	$609.00K	$611.00K

FEED Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.04M	-$3.60M	-$2.52M	-$9.37M
Capital Expenditure	-$3.00K	-$1.00K	-$3.00K	-$60.00K
Free Cash Flow	-$7.04M	-$3.60M	-$2.52M	-$9.43M
Depreciation & Amortisation	$1.00K	$1.00K	$1.00K	$897.00K
Stock-Based Compensation	$354.00K	$293.00K	$356.00K	$0.00
Investing Cash Flow	-$3.00K	-$1.00K	-$3.00K	$88.00K
Financing Cash Flow	$2.09M	$4.22M	$1.00K	$12.79M
Share Repurchases	—	—	$0.00	-$5.00M
Net Change in Cash	-$4.95M	$619.00K	-$2.52M	$3.50M

FEED Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.02M	$494.00K	$722.00K	$312.00K	$653.00K	$239.00K
Cost of Revenue	$656.00K	$529.00K	$533.00K	$682.00K	$708.00K	$505.00K
Gross Profit	$369.00K	-$35.00K	$189.00K	-$370.00K	-$55.00K	-$266.00K
Research & Development	$530.00K	$1.02M	$221.00K	$39.00K	$468.00K	$510.00K
Selling, General & Admin	$1.69M	$2.92M	$2.21M	$3.25M	$3.19M	$4.70M
Operating Expenses	$2.22M	$3.94M	$2.44M	$3.29M	$3.66M	$5.21M
Operating Income	-$1.85M	-$3.98M	-$2.25M	-$3.66M	-$3.71M	-$5.47M
EBITDA	-$1.79M	-$3.40M	$855.00K	-$6.51M	-$3.54M	-$4.65M
Pretax Income	-$1.86M	-$3.91M	$545.00K	-$13.27M	-$3.79M	-$4.90M
Income Tax	$15.00K	$62.00K	$35.00K	-$419.00K	$33.00K	-$2.00K
Net Income	-$1.87M	-$3.97M	$510.00K	-$12.85M	-$3.82M	-$4.90M
Diluted EPS	-29.90	-1.03	-0.91	—	-6.88	-1.98
Diluted Shares	62615	484566	858434	—	3.29M	6.16M

FEED Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$601.00K	$4.03M	$6.95M	$4.22M	$2.23M	$1.08M
Receivables	$1.24M	$626.00K	$792.00K	$543.00K	$725.00K	$498.00K
Inventory	$2.02M	$2.21M	$2.24M	$2.34M	$2.27M	$2.58M
Current Assets	$3.86M	$6.89M	$10.02M	$7.27M	$6.20M	$4.82M
Total Assets	$44.10M	$51.48M	$54.38M	$41.12M	$39.87M	$38.41M
Current Liabilities	$8.20M	$6.54M	$11.64M	$6.66M	$6.87M	$7.30M
Total Debt	$3.92M	$2.13M	$3.17M	$1.20M	$1.21M	$1.31M
Total Liabilities	$8.43M	$11.01M	$11.92M	$7.63M	$7.86M	$7.65M
Retained Earnings	-$72.30M	-$75.99M	-$76.86M	-$90.48M	-$112.14M	-$124.45M
Shareholders' Equity	$35.67M	$40.48M	$42.46M	$33.50M	$32.02M	$30.76M
Working Capital	-$4.34M	$349.00K	-$1.63M	$611.00K	-$668.00K	-$2.49M
Net Debt	$3.15M	—	—	—	—	—

FEED Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$1.34M	-$3.38M	-$1.97M	-$2.68M	-$4.31M	-$2.69M
Capital Expenditure	-$5.00K	-$4.00K	-$28.00K	-$23.00K	-$17.00K	-$27.00K
Free Cash Flow	-$1.35M	-$3.39M	-$2.00M	-$2.70M	-$4.33M	-$2.72M
Depreciation & Amortisation	$18.00K	$364.00K	$257.00K	$258.00K	$217.00K	$219.00K
Stock-Based Compensation	$0.00	$0.00	$0.00	$0.00	—	—
Investing Cash Flow	$143.00K	-$4.00K	-$28.00K	-$23.00K	-$17.00K	-$27.00K
Financing Cash Flow	$1.05M	$6.85M	$4.92M	-$34.00K	$2.34M	$1.59M
Share Repurchases	$0.00	$0.00	-$5.00M	$0.00	-$1.56M	-$1.48M
Net Change in Cash	-$150.00K	$3.46M	$2.92M	-$2.73M	-$1.99M	-$1.12M

Market Snapshot

About

ENvue Medical, Inc. is a medical device company developing innovative solutions for urological and gynecological applications. The company's product portfolio includes devices for female pelvic floor disorders and urinary incontinence treatment. ENvue Medical's proprietary technologies aim to provide minimally invasive treatment options that improve patient outcomes and quality of life. The company focuses on clinical validation through trials and regulatory approvals to support commercialization. Strategic priorities include expanding the product pipeline and building commercial infrastructure for market penetration.